Shanghai Junshi Bioscience (1877.HK) - Will Junshi Progress or Go Backwards Instead?
The article mainly analyzed Junshi in terms of the pipeline, commercialization strategy, the talents, the outlook, the related concerns, as well as...
263 Views
Sino Biopharmaceutical (1177.HK) - The Business, The Concerns, The Insights on Biopharma Valuation
This article analyzed Sino Biopharmaceutical in terms of the business performance, short-term catalyst, concerns about the outlook, and insights on...
320 Views
Asia Ex-Japan Positioning: India & Tech at Record Highs
In this analysis, we provide a detailed overview of investor positioning among 96 active Asia Ex-Japan funds with combined AUM of $80bn.
179 Views
The Stocks to Own in Asia – Vol. 34
Our research team constantly reviews the Asian markets to try to find interesting ideas based on Fundamentals or Valuation or Momentum or Risk or...
295 Views
Pre-IPO Shanghai Ark Biopharmaceutical - Insights on Pipeline and Related Concerns
The article mainly analyzed Ark Biopharmaceutical in terms of the important product candidates AK0529 (ziresovir) and AK3280 that entered the...
259 Views